CN113030147B - Evaluation method based on urine metabolite index under long-term monitoring - Google Patents
Evaluation method based on urine metabolite index under long-term monitoring Download PDFInfo
- Publication number
- CN113030147B CN113030147B CN202110279835.5A CN202110279835A CN113030147B CN 113030147 B CN113030147 B CN 113030147B CN 202110279835 A CN202110279835 A CN 202110279835A CN 113030147 B CN113030147 B CN 113030147B
- Authority
- CN
- China
- Prior art keywords
- index
- normal range
- detection
- frequency
- metabolite
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N24/00—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects
- G01N24/08—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
- G01N24/088—Assessment or manipulation of a chemical or biochemical reaction, e.g. verification whether a chemical reaction occurred or whether a ligand binds to a receptor in drug screening or assessing reaction kinetics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P90/00—Enabling technologies with a potential contribution to greenhouse gas [GHG] emissions mitigation
- Y02P90/30—Computing systems specially adapted for manufacturing
Landscapes
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- High Energy & Nuclear Physics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention discloses an evaluation method based on a urine metabolite index under long-term monitoring, which comprises the steps of recording a detection value of the metabolite index during each detection, and evaluating with the following two dimensions when the nth detection needs to be evaluated: (1) Detecting the urine metabolite index for the nth time, recording a detection value, and judging whether the detection value exceeds a normal range or not; (2) And processing all detection values, counting the frequency of the index exceeding the normal range, and respectively making a score standard for the amplitude of the average value of the index exceeding the normal range, and judging the fluctuation of the index in the time dimension by using the total score. Compared with the prior art, the method can solve the problem that the result evaluation is not comprehensive enough in the long-term monitoring process of the urine metabolite. The method introduces the fluctuation dimension in the normal range dimension, and uses the two-dimensional score to jointly reflect the change of the index, so that the specific condition of the metabolite during long-term monitoring can be better reflected in the time dimension.
Description
Technical Field
The invention belongs to the technical field of biology, and particularly relates to an evaluation method based on urine metabolite indexes under long-term monitoring.
Background
Metabolites are able to sensitively and rapidly respond to physiological changes and changes in body function, not only substrates in metabolic reactions, but also signaling molecules that control various cellular processes (PMID: 32641495). Urine, one of the main ways of excretion of metabolites in the human body, is the most common bodily fluid and is readily available and not as complex as other bodily fluids, so urine is the most suitable sample type for long-term monitoring of metabolites (PMID: 22971357).
However, urine metabolites are regulated and controlled by various factors, including diet, exercise, medicine, rest, mood and the like, and single detection often cannot fully reflect the health state of the body, so long-term monitoring is particularly important. Generally, our judgment on the index is based on the normal range of the index, but the normal range cannot meet the judgment on the index in the long-term monitoring process.
Disclosure of Invention
The invention aims to: in order to solve the technical problems, the invention provides an evaluation method based on urine metabolite indexes under long-term monitoring, which introduces the fluctuation dimension in the dimension of a normal range, and uses two-dimensional scoring to jointly reflect the change of indexes, so that the specific situation of the metabolites during long-term monitoring can be better reflected in the time dimension.
The technical scheme is as follows: an evaluation method based on urine metabolite indexes under long-term monitoring comprises the steps of recording detection values of metabolite indexes in each detection, and evaluating with the following two dimensions when the nth detection needs to be evaluated:
(1) Detecting the urine metabolite index for the nth time, recording a detection value, and judging whether the detection value exceeds a normal range or not;
(2) And processing all detection values, counting the frequency of the index exceeding the normal range, and respectively making a score standard for the amplitude of the average value of the index exceeding the normal range, and judging the fluctuation of the index in the time dimension by using the total score.
As a preferred or specific embodiment:
and the nth time, wherein n is more than or equal to 2.
The frequency exceeding the normal range is counted, the frequency exceeding the normal range of the index during the nth detection is divided by the total detection frequency n to obtain the frequency exceeding the normal range, the frequency exceeding the frequency is= (the frequency exceeding the frequency/the total frequency) 100, and the frequency is used as ten bits of the second dimension score in the range of 0-100.
The criteria for the score are as follows:
the amplitude of the average value exceeding the normal range is the average value of the index for n times, and the average value is divided by the upper limit of the normal range of the index, the magnitude of the index average exceeding the normal range is counted, the fluctuation magnitude=average/index upper limit, in the range of 0 to +++, the range of variation is taken as the bit of the second dimension score.
The criteria for the score are as follows:
the beneficial effects are that: compared with the prior art, the method can solve the problem that the result evaluation is not comprehensive enough in the long-term monitoring process of the urine metabolite. The method introduces the fluctuation dimension in the normal range dimension, and uses the two-dimensional score to jointly reflect the change of the index, so that the specific condition of the metabolite during long-term monitoring can be better reflected in the time dimension.
Detailed Description
The following description of the present invention will be given in terms of the best mode for carrying out the invention, but the present invention is not limited to the following examples.
EXAMPLE 1 Nuclear magnetic resonance method
1) Sample: the method detects random urine samples after meals, urine is collected into a urine collecting pipe without adding a reagent, and then the urine is centrifuged, sediment is discarded, and the urine can be detected to accept fresh urine or frozen urine.
2) Sample buffer solution preparation: potassium dihydrogen phosphate buffer solution 1.5mol/L, deuterated water as solvent and 0.1% TSP are fully dissolved and uniformly mixed, split charging and cold storage are carried out, and the temperature should be preheated to room temperature before each use.
3) Sample pretreatment: fresh or completely melted urine is placed at room temperature to restore the temperature and shaken up, 900ul of sample is taken and added into an EP tube containing 100ul of buffer solution, and after gentle and full mixing and shaking up, 600ul is transferred into a nuclear magnetic tube to wait for detection.
4) Sample detection: before sample data acquisition, the quality control standard substance is used for being qualified through nuclear magnetic self-inspection, so that the instrument state is good, the ambient temperature is stable, and the quantitative performance reaches the standard. In order to ensure the detection quality, the detected sample is stored at the temperature of 280K before detection, a temperature control flow is used for heating the sample in the detection process, and after the sample reaches the detection temperature (300K), the sample is ensured to be 1 H NMR Nosey spectra were collected. After the chemical shift was corrected by using TSP (trimethylsilylpropanoic acid) added to the buffer, the integral and quantitative analysis were performed according to the characteristic peak spectrum peak assignment of each metabolite.
5) Calculating a metabolic index two-dimensional score: and extracting detection results of all times of detection of the corresponding metabolic indexes of the detected person, and calculating a second-dimension score.
Urine metabolite index: taurine (normal range: 0-150):
| the tester | Age of | Sex (sex) | Physical condition |
| #1 | 51 | Man's body | Hypertension of the type |
| #2 | 31 | Female | Health care |
Both testers (# 1 and # 2) detected 180 in the 10 th test, and the second dimension score was different, although the test values of the index were outside the normal range: the #1 detector can lead taurine to exceed the normal range for a long time due to long-term administration of cardiovascular and cerebrovascular drugs, and the detection result of the #2 detector is in the normal range in most cases and only exceeds the detection result occasionally, so that the #1 is higher than the #2 second dimension score, the index is influenced by the drugs in abnormal and fluctuation in long-term monitoring, and the fluctuation condition of different people in the long-term monitoring process can be seen through the score.
The 10 th detection result and the second dimension score:
| the tester | Detection value | Second dimension score |
| #1 | 180 | 92 |
| #2 | 180 | 20 |
10 times of detection result original data:
example 2 liquid chromatography-Mass Spectrometry
1) Sample: the method detects that urine is collected into a urine collecting pipe without adding reagent aiming at a random urine sample after meal and is stored at-80 ℃ for standby.
2) Sample buffer solution preparation: extracting solution: methanol-acetonitrile (50:50, V/V).
3) Sample pretreatment: fresh or completely melted urine was allowed to warm at room temperature and shaken well, 100. Mu.L of urine sample was added with 400. Mu.L of the extract, left on ice for 10min, occasionally vortexed, centrifuged at 16000g for 10min to collect the supernatant, dried in vacuo, and reconstituted with 100. Mu.L of mobile phase containing standard of known concentration.
4) Sample detection: the sample is detected by a machine, firstly, the sample is separated by a C-18 column through a mobile phase, then, a spectrum of the sample is collected, and the integral and quantitative analysis are carried out according to the spectrum peak of each metabolite combined by the standard.
5) Calculating a metabolic index two-dimensional score: and extracting detection results of all times of detection of the corresponding metabolic indexes of the detected person, and calculating a second-dimension score.
Urine metabolite index: d-glucose (normal range: 0-63):
| the tester | Age of | Sex (sex) | Physical condition |
| #3 | 35 | Man's body | Health care |
| #4 | 32 | Man's body | Health care |
Both detectors (# 3 and # 4) detected 140 for the index at the 8 th detection, which is outside the normal range, but the second dimension score is different: the detection results of the #3 detector and the #4 detector are in the normal range in most cases in long-term monitoring, but the detection results of the #3 detector at the 7 th time are very high (2700), so that the second dimension score is higher than that of the #4 detector, the abnormality and fluctuation of the reaction #3 in long-term monitoring are larger than those of the #4 detector, and the fluctuation condition of different people in the long-term monitoring can be seen through the score.
The 8 th detection result and the second dimension score:
| the tester | Detection value | Second dimension score |
| #3 | 140 | 35 |
| #4 | 140 | 10 |
10 times of detection result original data:
Claims (4)
1. the method for evaluating the metabolite index of the urine based on long-term monitoring is characterized by comprising the steps of recording the detection value of the metabolite index during each detection, and evaluating with the following two dimensions when the nth detection needs to be evaluated:
(1) Detecting the urine metabolite index for the nth time, recording a detection value, and judging whether the detection value exceeds a normal range or not;
(2) Processing all detection values, counting the frequency of the index exceeding the normal range and the amplitude of the average value of the index exceeding the normal range, respectively making a score standard, and judging the fluctuation of the index in the time dimension by using the total score; counting the frequency of the index exceeding the normal range in the nth detection, dividing the frequency by the total detection frequency n to obtain the frequency exceeding the normal range, wherein the frequency exceeding the frequency is = (frequency exceeding/total frequency) 100, and the frequency is used as ten bits of a second dimension score in the range of 0-100; the amplitude of the average value exceeding the normal range is the average value of the index for n times, and the average value is divided by the upper limit of the normal range of the index, the magnitude of the index average exceeding the normal range is counted, the fluctuation magnitude=average/index upper limit, in the range of 0 to +++, the range of variation is taken as the bit of the second dimension score.
2. The method for evaluating an index of a metabolite of urine based on long-term monitoring according to claim 1, wherein n is 2 or more.
3. The method for evaluation of urine metabolite indicators based on long term monitoring according to claim 1, wherein the score criteria are as follows:
4. the method for evaluation of urine metabolite indicators based on long term monitoring according to claim 1, wherein the score criteria are as follows:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110279835.5A CN113030147B (en) | 2021-03-16 | 2021-03-16 | Evaluation method based on urine metabolite index under long-term monitoring |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110279835.5A CN113030147B (en) | 2021-03-16 | 2021-03-16 | Evaluation method based on urine metabolite index under long-term monitoring |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113030147A CN113030147A (en) | 2021-06-25 |
| CN113030147B true CN113030147B (en) | 2023-06-27 |
Family
ID=76470826
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110279835.5A Active CN113030147B (en) | 2021-03-16 | 2021-03-16 | Evaluation method based on urine metabolite index under long-term monitoring |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113030147B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008011797A (en) * | 2006-07-06 | 2008-01-24 | Nitta Gelatin Inc | Method for evaluating anticancer action |
| WO2017106363A1 (en) * | 2015-12-14 | 2017-06-22 | Parkinson's Institute | Refining diagnosis and treatment of complex multi-symptom neurological disorders |
| CN108344761A (en) * | 2018-02-10 | 2018-07-31 | 厦门大学 | A kind of the effect of electroacupuncture treatment atrophic gastritis evaluation method |
| CN109100436A (en) * | 2018-07-17 | 2018-12-28 | 成都益康谱科技有限公司 | The detection method of estrogen and its metabolite in human urine |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7949475B2 (en) * | 2005-08-08 | 2011-05-24 | Metabolon Inc. | System and method for analyzing metabolomic data |
| CN108334752B (en) * | 2017-01-20 | 2020-09-04 | 北京松果天目健康管理有限公司 | Method for establishing quantitative reference range of healthy human urine proteome and healthy human urine proteome database |
| CN110604555A (en) * | 2018-06-15 | 2019-12-24 | 北京东方兴企食品工业技术有限公司 | System for evaluating hypertension risk |
| CN110108891A (en) * | 2018-11-15 | 2019-08-09 | 许兵 | A kind of urine and stool automation detection and control system and method for intelligent closestool |
| CN110796073B (en) * | 2019-10-28 | 2021-05-25 | 衢州学院 | Method and device for detecting specific target area in non-texture scene video |
| CN111110249B (en) * | 2019-12-27 | 2021-08-27 | 中国科学院深圳先进技术研究院 | Blood glucose fluctuation evaluation method and evaluation device |
-
2021
- 2021-03-16 CN CN202110279835.5A patent/CN113030147B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008011797A (en) * | 2006-07-06 | 2008-01-24 | Nitta Gelatin Inc | Method for evaluating anticancer action |
| WO2017106363A1 (en) * | 2015-12-14 | 2017-06-22 | Parkinson's Institute | Refining diagnosis and treatment of complex multi-symptom neurological disorders |
| CN108344761A (en) * | 2018-02-10 | 2018-07-31 | 厦门大学 | A kind of the effect of electroacupuncture treatment atrophic gastritis evaluation method |
| CN109100436A (en) * | 2018-07-17 | 2018-12-28 | 成都益康谱科技有限公司 | The detection method of estrogen and its metabolite in human urine |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113030147A (en) | 2021-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105219844B (en) | Gene marker combination, kit and the disease risks prediction model of a kind of a kind of disease of screening ten | |
| Thomas et al. | Exhaled breath condensate in pediatric asthma: promising new advance or pouring cold water on a lot of hot air? A systematic review | |
| Lyman | Blood urea nitrogen and creatinine | |
| CN104651513B (en) | A kind of detection method of gout serum miRNAs biomarkers and its expression quantity | |
| CN111458447B (en) | Chinese wolfberry quality detection method based on spectral efficiency relationship | |
| CN113030301B (en) | Application of LPE (16:0) in preparation of kit for early diagnosis of diabetic nephropathy | |
| CN109055538A (en) | A kind of the excretion body miRNA marker and kit of rheumatoid arthritis | |
| de Gonzalo-Calvo et al. | Plasma microRNA profiling reveals novel biomarkers of epicardial adipose tissue: a multidetector computed tomography study | |
| Thompson et al. | Environmental, dietary, and behavioral factors distinguish Chinese adults with high waist-to-height ratio with and without inflammation | |
| CN113030147B (en) | Evaluation method based on urine metabolite index under long-term monitoring | |
| Tu et al. | Characteristics of a new urine, serum, and saliva alcohol reagent strip | |
| CN102262098A (en) | Rheumatoid arthritis spectrum model and construction method thereof | |
| CN115472231B (en) | Type2diabetes detecting system based on intestinal flora | |
| CN111721882A (en) | Metabonomics marker kit for self-assembly detection of postoperative delirium and application | |
| CN113125615B (en) | Application of three metabolic markers in preparation of kit for diagnosing Systemic Lupus Erythematosus (SLE) independently or jointly | |
| CN113539478B (en) | Metabolic omics-based deep vein thrombosis prediction model establishing method | |
| CN112763732B (en) | Application of PE (16:0/20:2) and composition thereof in diagnosis of diabetes and diabetic nephropathy | |
| Winkelman et al. | Estimation of norms from a controlled sample survey. II. Influence of body habitus, oral contraceptives, and other factors on values for the normal range derived from the SMA 12/60 screening group of tests | |
| CN114894926A (en) | Bile acid detection method based on dry blood paper sheet method | |
| CN112946303A (en) | Application of TAG54:2-FA18:1 and composition thereof in diagnosis of diabetes and diabetic nephropathy | |
| CN111269957A (en) | Colorimetric method based detection of NAD in biological sample+Method for content and application thereof | |
| Ahmadi et al. | Investigating the Efficiency of D-Dimer Test in the Diagnosis of Aortic Dissection: a systematic and meta-analysis study | |
| Ong et al. | The LaBrosse VMA spot test revisited | |
| CN111638324B (en) | Coronary heart disease diagnosis biomarker composition and application thereof | |
| CN114563504B (en) | Method and kit for determining content of free aldosterone in blood plasma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Li Jie Inventor after: Qin Di Inventor after: Yan Haojie Inventor before: Li Jie Inventor before: Qin Di Inventor before: Yan Lijie |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |